De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Circio Holding Beheer

Beheer criteriumcontroles 4/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Erik Wiklund

Algemeen directeur

NOK 2.6m

Totale compensatie

Percentage CEO-salaris	95.7%
Dienstverband CEO	3yrs
Eigendom CEO	0.6%
Management gemiddelde ambtstermijn	3yrs
Gemiddelde ambtstermijn bestuur	4.3yrs

Recente managementupdates

Circio Holding ASA's (OB:CRNA) CEO Will Probably Struggle To See A Pay Rise This Year

May 29

Recent updates

Circio Holding ASA's (OB:CRNA) CEO Will Probably Struggle To See A Pay Rise This Year

May 29

Targovax ASA's (OB:TRVX) Intrinsic Value Is Potentially 96% Above Its Share Price

Aug 24

Shareholders May Be A Bit More Conservative With Targovax ASA's (OB:TRVX) CEO Compensation For Now

Mar 10

Is Targovax (OB:TRVX) Using Debt In A Risky Way?

Feb 20

The Chief Scientific Officer of Targovax ASA (OB:TRVX), Victor Levitsky, Just Bought A Few More Shares

Dec 05

Analyse CEO-vergoeding

Hoe is Erik Wiklund's beloning veranderd ten opzichte van Circio Holding's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	NOK 9m
Mar 31 2024	n/a	n/a	-NOK 51m
Dec 31 2023	NOK 3m	NOK 2m	-NOK 111m
Sep 30 2023	n/a	n/a	-NOK 446m
Jun 30 2023	n/a	n/a	-NOK 449m
Mar 31 2023	n/a	n/a	-NOK 440m
Dec 31 2022	NOK 4m	NOK 3m	-NOK 433m
Sep 30 2022	n/a	n/a	-NOK 107m
Jun 30 2022	n/a	n/a	-NOK 110m
Mar 31 2022	n/a	n/a	-NOK 106m
Dec 31 2021	NOK 3m	NOK 2m	-NOK 98m
Sep 30 2021	n/a	n/a	-NOK 98m
Jun 30 2021	n/a	n/a	-NOK 97m
Mar 31 2021	n/a	n/a	-NOK 105m
Dec 31 2020	NOK 3m	NOK 2m	-NOK 108m
Sep 30 2020	n/a	n/a	-NOK 117m
Jun 30 2020	n/a	n/a	-NOK 120m
Mar 31 2020	n/a	n/a	-NOK 132m
Dec 31 2019	NOK 2m	NOK 2m	-NOK 148m
Sep 30 2019	n/a	n/a	-NOK 153m
Jun 30 2019	n/a	n/a	-NOK 162m
Mar 31 2019	n/a	n/a	-NOK 153m
Dec 31 2018	NOK 2m	NOK 2m	-NOK 147m
Sep 30 2018	n/a	n/a	-NOK 139m
Jun 30 2018	n/a	n/a	-NOK 132m
Mar 31 2018	n/a	n/a	-NOK 129m
Dec 31 2017	NOK 942k	NOK 883k	-NOK 122m

Compensatie versus markt: De totale vergoeding ($USD 245.26K ) Erik } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Norwegian markt ($USD 314.60K ).

Compensatie versus inkomsten: De vergoeding van Erik is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Erik Wiklund

3yrs

Tenure

NOK 2,603,000

Compensatie

Dr. Erik Digman Wiklund serves as Chief Executive Officer of Circio Holding ASA (formerly known as Targovax ASA) since October 2021 and had been its Chief Business Officer since September 24, 2018 until Oc...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Erik Wiklund	Chief Executive Officer	3yrs	NOK 2.60m	0.59% NOK 96.3k
Lubor Gaal	CFO & Head of BD	2.6yrs	NOK 2.88m	0.38% NOK 62.7k
Ola Melin	Chief Operating Officer	less than a year	NOK 1.97m	0.20% NOK 32.5k
Thomas Hansen	Chief Technology Officer	less than a year	NOK 1.97m	0.19% NOK 31.4k
Victor Levitsky	Chief Scientific Officer	4.4yrs	NOK 790.00k	0.19% NOK 31.6k
Jon Eriksen	Special Advisor	6.8yrs	NOK 1.86m	geen gegevens
Gustav Gaudernack	Chief Scientific Adviser	no data	geen gegevens	geen gegevens
Peter Skorpil	Vice President of Business Development	9.5yrs	NOK 1.07m	geen gegevens

3.0yrs

Gemiddelde duur

Ervaren management: Het managementteam van CRNA wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Diane Mellett	Independent Non-Executive Director	9.1yrs	NOK 371.00k	0.53% NOK 87.4k
Thomas Falck	Director	2.5yrs	NOK 357.00k	0.38% NOK 62.7k
Robert Burns	Independent Director	9.3yrs	NOK 352.00k	0.28% NOK 45.9k
Damian Marron	Chairman of the Board	4.5yrs	NOK 589.00k	0.69% NOK 113.4k
Dmitriy Zamarin	Member of Medical Advisory Board	4yrs	geen gegevens	geen gegevens
Dean Fennell	Member of Scientific Advisory Board	4yrs	geen gegevens	geen gegevens

4.3yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CRNA wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Circio Holding Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Circio Holding ASA's (OB:CRNA) CEO Will Probably Struggle To See A Pay Rise This Year

Circio Holding ASA, Annual General Meeting, Jun 05, 2024

High number of new directors

High number of new directors

Targovax ASA Announces Board Changes

Targovax ASA Appoints Lubor Gaal as Chief Financial Officer, Effective March 7, 2022

Recent updates

New major risk - Revenue and earnings growth

Investor sentiment deteriorates as stock falls 18%

New major risk - Financial position

Circio Announces Strengthened in Vivo Data and Enhanced Circvec 2.2 Design

New major risk - Shareholder dilution

Circio Holding ASA's (OB:CRNA) CEO Will Probably Struggle To See A Pay Rise This Year

Circio Holding ASA has filed a Follow-on Equity Offering in the amount of NOK 60 million.

Circio Announces in Vivo Proof-Of-Concept for Its circVec circular RNA Platform Technology and Reinforced Gene Therapy Focus

Forecast breakeven date pushed back to 2026

Price target decreased by 32% to kr48.00

New major risk - Share price stability

New minor risk - Financial data availability

Price target increased by 60% to kr120

Circio Holding ASA Announces Dosing of First Patient in the Collaborative Phase 2 Trial Sponsored by Georgetown University

Circio Holding ASA, Annual General Meeting, Jun 05, 2024

IOVaxis Therapeutics Files Updated TG01 Investigational New Drug Application with the Chinese National Medical Products Administration

Circio Holding ASA Announces Completion of Planned Safety Review and Opening for Full Enrollment of TG01 Study At Oslo University Hospital

New major risk - Financial position

New major risk - Market cap size

Price target increased by 14% to kr4.00

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Targovax Announces That the TG01 Study in Multiple Myeloma At Oslo University Hospital Has Received Regulatory Approvals to Proceed

Targovax ASA to Report Q3, 2023 Results on Nov 09, 2023

High number of new directors

Targovax ASA Completes ONCOS-102 Phase 1b Study in PD-1 CPI Resistant Advanced Melanoma Has Been Published in the Oncology Journal Clinical Cancer Research

Targovax ASA Receives Approval to Proceed with the Oncos-102 Phase 2 Melanoma Study from the US FDA

Targovax ASA's (OB:TRVX) Intrinsic Value Is Potentially 96% Above Its Share Price

No longer forecast to breakeven

Health Check: How Prudently Does Targovax (OB:TRVX) Use Debt?

Targovax ASA Announces that the FDA Grant Authorization to Initiate Clinical Trials with the Enhanced TG01 RAS Vaccine in the USA

Price target decreased to kr3.30

Price target decreased to kr3.75

High number of new directors

Targovax ASA Announces Board Changes

Forecast to breakeven in 2024

Targovax ASA Appoints Lubor Gaal as Chief Financial Officer, Effective March 7, 2022

Forecast to breakeven in 2024

Targovax ASA Announces ONCOS-102 Achieves 25.0 Months Median Overall Survival in First Line Mesothelioma

Chief Executive Officer recently bought kr201k worth of stock

Independent Director exercised options to buy kr204k worth of stock.

Is Targovax (OB:TRVX) Using Debt In A Risky Way?

Chief Financial Officer Torbjørn Furuseth has left the company

Price target decreased to kr13.83

Is Targovax (OB:TRVX) A Risky Investment?

Targovax Receives Fast Track Designation for Oncos-102 in Melanoma

Targovax Announces Completed Enrollment in the Phase 1/2 Trial with ONCOS-102 in Combination with Durvalumab in Patients with Advanced Colorectal Cancer with Peritoneal Malignancies

Targovax ASA's ONCOS-102 Mesothelioma 24-Month Data Shows Class-Leading Median Overall Survival

Targovax ASA Announces Board Changes

Shareholders May Be A Bit More Conservative With Targovax ASA's (OB:TRVX) CEO Compensation For Now

Targovax Granted US Patent for Oncos-102 in Combination with Checkpoint Inhibitors

Analysts update estimates

Continued Survival Benefit in Targovax's ONCOS-102 Trial in Mesothelioma At the 21-Month Follow-Up

Earnings beat expectations, revenue disappoints

Is Targovax (OB:TRVX) Using Debt In A Risky Way?

Targovax ASA Receives Fast-Track Designation for ONCOS-102

Targovax ASA and Papyrus Therapeutics Enter Research Collaboration to Develop Novel ONCOS Viruses with Receptor Tyrosine Kinase (RTK) Inhibitor Functionality

Targovax grants IOVaxis 3 months extension to the exclusive license option for TG mutant RAS vaccines in Greater China and Singapore

New 90-day high: kr10.90

Chief Scientific Officer recently bought kr100k worth of stock

The Chief Scientific Officer of Targovax ASA (OB:TRVX), Victor Levitsky, Just Bought A Few More Shares

New 90-day high: kr9.50

Chief Scientific Officer recently bought kr100k worth of stock

Targovax ASA Demonstrates Encouraging Survival Data for Oncos-102 in Mesothelioma

Analysts increase revenue estimates to kr7.28m

Earnings miss expectations

Targovax ASA to Report Q1, 2021 Final Results on May 06, 2021

Targovax Announces Formation of New Scientific Advisory Board

New 90-day low: kr5.97